2 research outputs found
Sensitive Trimodal Magnetic Resonance Imaging-Surface-Enhanced Resonance Raman Scattering-Fluorescence Detection of Cancer Cells with Stable Magneto-Plasmonic Nanoprobes
Novel magneto-plasmonic nanoprobes
were designed for multimodal
diagnosis of cancer by combination of magnetic resonance imaging (MRI),
surface-enhanced resonance Raman scattering (SERRS), and fluorescence
emission in the very near infrared (VNIR). A controlled electrostatic
assembly of silver nanoparticles (AgNPs), superparamagnetic iron oxide
nanoparticles (SPIONs), VNIR dye Nile Blue (NB), and biopolymer chitosan
(Chi) was used to formulate the AgIONs-Chi nanoprobes. The formulation
protocol did not involve organic solvents and was rapid and efficient
as confirmed by magnetic sorting. The SERRS response of the nanoprobes
was very intense and constant for days. It decreased linearly upon
1000-fold dilution and was still recognizable at 0.1 nM NB concentration.
After 30 days of storage, the SERRS loss was less than 30% and the
hydrodynamic size of the AgIONs-Chi in PBS remained below 200 nm.
The gradual decrease of the ratio SERRS/fluorescence allowed one to
monitor the release of the fluorescent molecule upon long-term nanoprobe
dissociation. The AgIONs-Chi exhibited 2-fold higher MRI contrast
than that of commercially available SPION suspensions. Finally, the
nanoprobes were actively uptaken by HeLa cancer cells and ensured
trimodal MRI-SERRS-fluorescence detection of 10 μL cell inclusions
in cm-sized agarose gels used here as phantom models of microtumors.
The above results show that the magneto-plasmonic AgIONs-Chi are promising
substrates for SERRS analysis in solution and for multimodal imaging
of cancer cells
MOESM1 of Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
Additional file 1: Fig. S1. Nanoprobe purification step measured by ELISA. Fig. S2. DLS, zeta and fluorescence characterization of nanoprobes. Fig. S3. HER2 quantification on breast cancer xenograft by flow cytometry. Fig. S4. MRI biodistribution of nanoprobes in liver, spleen and kidneys